26 March 2021 | News
Multi-year agreement to expand commercial footprint with world-leading genomics platform and develop R&D to unlock the potential of multimodal health data
Image credit- shutterstock.com
Japanese firm Hitachi and American Swiss biotech company Sophia Genetics have announced that they have entered into a long-term collaboration agreement to bring clinical, genomic and real-world insights to healthcare providers, pharmaceutical and biopharmaceutical companies and extend the democratization of Data-Driven Precision Medicine globally for the benefit of patients.
Under this agreement, the two companies will advance data-driven precision medicine through global commercial expansion and development of Hitachi's digital healthcare solutions and the SOPHiA DDM™ Platform.
SOPHiA GENETICS and Hitachi have identified multiple areas for potential collaboration including secure personal genomics data management, deployment of data and insights for better healthcare decisions and acceleration of drug development in oncology and other disease areas.
Initially, the collaboration will focus on leveraging the genomics, clinical data analytics and AI expertise of both companies to expand the commercialization of the SOPHiA DDM™ Platform and Hitachi's digital healthcare solutions, like Hitachi's molecular tumor board support service, in key geographies.
Over the long term, the two companies will also collaborate on R&D related new product development which is expected to lead to new joint offerings.